חוב כולל להון Coeptis Therapeutics (COEP)

Coeptis Therapeutics (COEP) is actively developing personalized methods for combating hematological tumors in the R&D stage. The company's price chart demonstrates the 0.02 indicator. The business relies on external contractors for drug production and the conduct of trials. Simultaneously, the brand is strengthening its image as an innovator by creating platforms to enhance patient immunity in the fight against blood cancer.

This indicator is calculated as the ratio of total liabilities to net equity, reflecting the dependence of operational stability on external financing. For Coeptis Therapeutics (COEP), which develops advanced blood cancer therapies, this debt-to-equity coverage ratio demonstrates the balance between investments in R&D-intensive developments and insolvency risks amid market volatility.